Tag: PSA

PCa17: Interactive, compact meeting opens in Vienna

Challenges in diagnosis, staging and patient selection were among the issues taken up in the first plenary session of the EAU Update on Prostate Cancer (PCa17) opened in Vienna today. With more than 300 participants including faculty and exhibitors,...

Where do we stand with predictive biomarkers in mCRPC?

Treatment options for men with metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, cabazitaxel and radium-2231-6. With evidence that both abiraterone acetate and enzalutamide are effective agents when administered...